Vol. 3 No. 11 (2023)
Reimbursement Recommendations

Axicabtagene ciloleucel (Yescarta)

Published November 21, 2023

Key Messages

  • CADTH recommends that Yescarta be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) if certain conditions are met.
  • Yescarta should only be covered to treat adult patients who have grade 1, 2, or 3a FL whose disease has returned following second-line treatment or later lines of treatments.
  • Yescarta should only be reimbursed for patients who have not already received a chimeric antigen receptor (CAR) T-cell therapy and are in relatively good health, and if the cost of Yescarta is reduced. Yescarta should be prescribed and administered by clinicians with expertise in blood cancers in a hospital setting with adequate resources to treat patients and manage side effects.